Pharmacology of Neuromuscular Blocking Drugs and AnticholinesterasesFor practical purposes, mono quaternary aminosteroid their structure—activity relationship SAR is a rational way to understand their actions and metabolism. A review by Hill mono quaternary aminosteroid colleagues summarized contributions by previous reviewers and provided details on several series of compounds. The classic experiments of Aminoteroid Bernard led to quaternarg recognition of hgh energizer for sale anatomical gap between motor nerve and skeletal muscle. It has two mono quaternary aminosteroid quaternary onium heads Fig. In the conception of atracurium, the acyl group was designed to break away under physiological pH and temperature, leaving the tertiary benzylisoquinoline product laudanosine Fig. Ach is a flexible molecule capable of adopting several conformations without significant energy penalty.
Neuromuscular blocking drugs
Neuromuscular blocking drugs NMBDs are used in anaesthesia to impair neuromuscular transmission and provide skeletal muscle relaxation. These drugs enable the anaesthetist to perform tracheal intubation, facilitate ventilation and to provide optimal surgical operating conditions, for example during laparotomy.
NMBDs are quaternary ammonium compounds structurally similar to acetylcholine ACh ; they act mostly at the post-junctional nicotinic receptor of the neuromuscular junction. Anticholinesterase drugs also known as acetylcholinesterase inhibitors are used to reverse the effects of non-depolarizing NMBDs.
These drugs increase the concentration of ACh at the neuromuscular junction by inhibiting the enzyme acetylcholinesterase. Suxamethonium succinylcholine is the only depolarizing NMBD in clinical use. Structurally it is two ACh molecules joined together and it acts as an agonist at the nicotinic receptor. Suxamethonium binds with the two alpha sub-units of the receptor mimicking ACh resulting in membrane depolarization. When depolarization occurs it causes muscle contraction, which occurs rapidly and is observed clinically as muscle fasciculation.
After depolarization the membrane potential must be reset before further depolarization can occur and skeletal muscle remains in a state of flaccid relaxation until this occurs. An intravenous dose of suxamethonium of 1. The blockade typically resolves spontaneously after approximately 10 minutes. Suxamethonium results in a Phase I block, characterised by absence of fade and post-tetanic facilitation on peripheral nerve stimulation.
Suxamethonium is hydrolysed rapidly by plasma cholinesterase to succinyl monocholine and choline. Prior to use it is stored at 4 degrees Celsius to prevent hydrolysis. Although not commonly used, an infusion of suxamethonium can be used to produce prolonged neuromuscular blockade. Pre-treatment with atropine is required if this technique is used.
The onset is considerably slower that when given intravenously. This route is usually used only in infants where venous access is not possible. Suxamethonium is the NMBD with the most rapid and predictable onset of action.
This and the fact that it has a short duration of action mean that it is the drug of choice for anaesthesia when a rapid sequence induction RSI is used for patients at risk of aspiration, or when rapid tracheal intubation is required in an emergency situation.
It is also indicated when rapid recovery of neuromuscular function may be required. Occurs due to stimulation of muscarinic receptors in the sino-atrial node. Bradycardia is more common in children and after repeated doses of the drug.
There is a theoretical risk of expulsion of vitreal contents with the use of suxamethonium in patients with a penetrating eye injury. This risk must be balanced with the risk of aspiration of gastric contents in emergency surgery. Occurs commonly, especially in young, fit adults with early ambulation. Strategies such as precurarization exist to reduce the incidence but no strategy is fully preventative. Average serum potassium levels increase by 0. Patients with pre-existing hyperkalaemia are at risk of cardiac arrhythmias and death.
Fatal hyperkalaemia can occur in burns patients, patients with muscular dystrophies and paraplegic patients. This may be due to proliferation of extra-junctional receptors in these patients.
Maximal risk of hyperkalaemia in burn patients occurs during days after the burn. The use of suxamethonium within the first days after a severe burn injury is regarded as safe. This is offset by an increase in oesophageal barrier pressure. This may occur after large or repeated doses of suxamethonium.
Neuromuscular block is prolonged and peripheral nerve stimulation results in fade of the train-of-four twitch height response and post tetanic facilitation. Prolonged block due to reduced plasma cholinesterase activity. This may be due to congenital or acquired causes.
Acquired causes include reduced enzyme synthesis, which may occur in liver disease, carcinomatosis, pregnancy or starvation hypoproteinaemic states , cardiac failure, renal failure, and burns.
The co-administration of other drugs such as etomidate, ester local anaesthetics, methotrexate, remifentanil and esmolol can result in a reduction in plasma cholinesterase activity. Inherited causes of prolonged block after suxamethonium occur due to production of atypical plasma cholinesterase.
Three variants from the usual gene exist and are known as the atypical, silent and fluoride resistant genes. Individuals with these variant genes have atypical cholinesterase enzyme, and have a prolonged neuromuscular block after suxamethonium. Duration of prolonged block varies from 30 minutes eg. This condition may be triggered by suxamethonium and therefore its use is absolutely contraindicated in susceptible patients. Non-depolarizing drugs are competitive antagonists of ACh at the postsynaptic nicotinic receptor.
They bind to one or both alpha subunits of the receptor and prevent depolarization due to ACh. The binding of antagonists to the receptor is reversible and repeated association and dissociation occurs. Non-depolarizing NMBDs are also believed to have an action at pre-junctional receptors at the neuromuscular junction.
Stimulation of pre-junctional receptors by ACh normally results in further mobilisation of ACh to cope with increasing stimulation frequency. Non-depolarizing NMBDs antagonise these receptors and inhibit this process. When assessing the block caused by non-depolarizing NMBDs with a peripheral nerve stimulator a characteristic response is observed.
Fade of twitch height response occurs during a train of four or tetanic pattern of stimulation. Fade is due to the action of these drugs at the presynaptic receptor resulting in reduced availability of ACh with repeated nerve stimulation. Post tetanic facilitation of neuromuscular transmission is another feature of non-depolarizing neuromuscular blockade and is due to increased quantities of ACh in the synapse of the junction after tetanic stimulation.
Non-depolarizing NMBDs are not metabolised at the neuromuscular junction and resolution of block is due to a dilutional effect of the drug with time. They are highly ionised, water-soluble drugs and their volume of distribution approximates to that of plasma and extracellular fluid. There are two groups of non-depolarizing NMBDs, benzylisoquinolinium compounds and aminosteroid compounds. These drugs consist of two quaternary ammonium groups joined by a chain of methyl groups.
They are more liable to break down in the plasma and often cause release of histamine; examples include tubocurarine, atracurium, cisatracurium and mivacurium. A drug with a long onset and prolonged duration of action see Table 1. It causes marked histamine release, with hypotension and tachycardia. Ganglion blockade may occur with large doses. Tubocurarine is excreted unchanged mostly in the urine but also in bile. Its effects are prolonged in renal failure. It has been superseded by agents with better side effect profiles and is no longer available in the UK.
A racemic mixture of 10 stereoisomers and geometric isomers. Atracurium has an intermediate onset and duration of action. It causes release of histamine but has no direct cardiovascular effects.
Metabolism is by Hofmann degradation and ester hydrolysis in the plasma, hence its duration of action is independent of renal and hepatic function.
Unlike atracurium it does not release histamine. It is metabolised by Hofmann degradation and does not accumulate in renal failure. Mivacurium is a drug with a short duration of action of approximately 15 minutes, making it potentially useful for short procedures. It is a racemic mixture of three isomers that is hydrolysed by plasma cholinesterase. Mivacurium is associated with histamine release causing significant hypotension with doses greater than 0. Like suxamethonium its duration of action is increased in patients with atypical plasma cholinesterase.
All aminosteroid NMBDs posses at least one quaternary ammonium group attached to a steroid nucleus. They tend not to cause histamine release and most are metabolised in an end organ before excretion. The first steroid NMBD in clinical use has a slow onset and long duration of action. It does not cause histamine release but has weak sympathomimetic properties and causes tachycardia. It is partly de-acylated in the liver to a metabolite with neuromuscular blocking properties, and partly excreted unchanged in the urine.
Its action is prolonged in renal and hepatic impairment. Vecuronium is structurally similar to pancuronium but has a slightly faster onset and shorter intermediate duration of action. It does not release histamine or have any cardiovascular effects. Metabolism in the liver occurs to active metabolites before being excreted in the bile and urine.
Vecuronium is unstable in solution and is stored as powder and requires mixing with water prior to administration. This monoquaternary amine has the most rapid onset of the clinically available non-depolarizing NMBDs. Intubating conditions can be achieved in seconds after an induction dose of 0. Rocuronium has an intermediate duration of action and is metabolised in the liver and excreted in the bile.
Rocuronium has minimal cardiovascular effects and does not release histamine, however, it has a higher incidence of anaphylactic reactions than other aminosteroid NMBDs. Anticholinesterases also known as acetylcholinesterase inhibitors are agents that inhibit the action of the acetylcholinesterase enzyme at the neuromuscular junction.
Enzyme inhibition leads to a reduction in the breakdown of ACh and potentiates its action. Anticholinesterases are used in anaesthesia to reverse the effects of non-depolarizing NMBDs. Reversal of non-depolarizing neuromuscular blockade usually occurs at the end of surgery, and should not take place before some resolution of the block has already occurred. Early administration of anticholinesterase may be ineffective due to high receptor occupancy by the NMBD.
Reversal of intermediate acting NMBDs with anticholinesterase should be at least 20 minutes after giving the drug. If peripheral nerve stimulation is used, at least 3 twitches on a train of four should be detected before attempting reversal. The most reliable sign that a block is fully reversed by anticholinesterase is a sustained response to tetanic stimulation with a peripheral nerve stimulator i.